121 related articles for article (PubMed ID: 15900025)
1. Dysfunction of the brain calcium channel CaV2.1 in absence epilepsy and episodic ataxia--a comment.
Strupp M; Kalla R; Freilinger T; Dichgans M; Brandt T
Brain; 2005 Jun; 128(Pt 6):E32; author reply E33. PubMed ID: 15900025
[No Abstract] [Full Text] [Related]
2. Dysfunction of the brain calcium channel CaV2.1 in absence epilepsy and episodic ataxia.
Imbrici P; Jaffe SL; Eunson LH; Davies NP; Herd C; Robertson R; Kullmann DM; Hanna MG
Brain; 2004 Dec; 127(Pt 12):2682-92. PubMed ID: 15483044
[TBL] [Abstract][Full Text] [Related]
3. Combination of BK channel opener and Kv4 channel inhibitor for treatment of cerebellar ataxia in mutant med mice.
Abbasi S; Abbasi A; Sarbaz Y
J Neuropsychiatry Clin Neurosci; 2013; 25(4):E41. PubMed ID: 24247886
[No Abstract] [Full Text] [Related]
4. Potassium channel blocker 4-aminopyridine is effective in interictal cerebellar symptoms in episodic ataxia type 2--a video case report.
Löhle M; Schrempf W; Wolz M; Reichmann H; Storch A
Mov Disord; 2008 Jul; 23(9):1314-6. PubMed ID: 18442126
[TBL] [Abstract][Full Text] [Related]
5. Experience in a short-term trial with 4-aminopyridine in cerebellar ataxia.
Giordano I; Bogdanow M; Jacobi H; Jahn K; Minnerop M; Schoels L; Synofzik M; Teufel J; Klockgether T
J Neurol; 2013 Aug; 260(8):2175-6. PubMed ID: 23824358
[No Abstract] [Full Text] [Related]
6. Treatment of the gravity dependence of downbeat nystagmus with 3,4-diaminopyridine.
Sprenger A; Rambold H; Sander T; Marti S; Weber K; Straumann D; Helmchen C
Neurology; 2006 Sep; 67(5):905-7. PubMed ID: 16966567
[TBL] [Abstract][Full Text] [Related]
7. 4-Aminopyridine improves gait variability in cerebellar ataxia due to CACNA 1A mutation.
Schniepp R; Wuehr M; Ackl N; Danek A; Brandt T; Strupp M; Jahn K
J Neurol; 2011 Sep; 258(9):1708-11. PubMed ID: 21431381
[No Abstract] [Full Text] [Related]
8. The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia.
Alviña K; Khodakhah K
J Neurosci; 2010 May; 30(21):7258-68. PubMed ID: 20505092
[TBL] [Abstract][Full Text] [Related]
9. Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine.
Strupp M; Kalla R; Dichgans M; Freilinger T; Glasauer S; Brandt T
Neurology; 2004 May; 62(9):1623-5. PubMed ID: 15136697
[TBL] [Abstract][Full Text] [Related]
10. Effects of dalfampridine on attacks in patients with episodic ataxia type 2: an observational study.
Claassen J; Teufel J; Kalla R; Spiegel R; Strupp M
J Neurol; 2013 Feb; 260(2):668-9. PubMed ID: 23183922
[No Abstract] [Full Text] [Related]
11. A CaV2.1 calcium channel mutation rocker reduces the number of postsynaptic AMPA receptors in parallel fiber-Purkinje cell synapses.
Kodama T; Itsukaichi-Nishida Y; Fukazawa Y; Wakamori M; Miyata M; Molnar E; Mori Y; Shigemoto R; Imoto K
Eur J Neurosci; 2006 Dec; 24(11):2993-3007. PubMed ID: 17156361
[TBL] [Abstract][Full Text] [Related]
12. Acetylcholine release at neuromuscular junctions of adult tottering mice is controlled by N-(cav2.2) and R-type (cav2.3) but not L-type (cav1.2) Ca2+ channels.
Pardo NE; Hajela RK; Atchison WD
J Pharmacol Exp Ther; 2006 Dec; 319(3):1009-20. PubMed ID: 16982704
[TBL] [Abstract][Full Text] [Related]
13. Update on the Pharmacotherapy of Cerebellar Ataxia and Nystagmus.
Feil K; Bremova T; Muth C; Schniepp R; Teufel J; Strupp M
Cerebellum; 2016 Feb; 15(1):38-42. PubMed ID: 26519380
[TBL] [Abstract][Full Text] [Related]
14. Loss of calcium channels in the cerebellum of the ataxic and epileptic stargazer mutant mouse.
Leitch B; Shevtsova O; Guévremont D; Williams J
Brain Res; 2009 Jul; 1279():156-67. PubMed ID: 19422811
[TBL] [Abstract][Full Text] [Related]
15. Alternative splicing generates a smaller assortment of CaV2.1 transcripts in cerebellar Purkinje cells than in the cerebellum.
Kanumilli S; Tringham EW; Payne CE; Dupere JR; Venkateswarlu K; Usowicz MM
Physiol Genomics; 2006 Jan; 24(2):86-96. PubMed ID: 16278278
[TBL] [Abstract][Full Text] [Related]
16. Abnormal excitability and episodic low-frequency oscillations in the cerebral cortex of the tottering mouse.
Cramer SW; Popa LS; Carter RE; Chen G; Ebner TJ
J Neurosci; 2015 Apr; 35(14):5664-79. PubMed ID: 25855180
[TBL] [Abstract][Full Text] [Related]
17. Fluctuating neuromuscular transmission defects and inverse acetazolamide response in episodic ataxia type 2 associated with the novel CaV2.1 single amino acid substitution R2090Q.
Melzer N; Classen J; Reiners K; Buttmann M
J Neurol Sci; 2010 Sep; 296(1-2):104-6. PubMed ID: 20663518
[TBL] [Abstract][Full Text] [Related]
18. Early onset, non fluctuating spinocerebellar ataxia and a novel missense mutation in CACNA1A gene.
Tonelli A; D'Angelo MG; Salati R; Villa L; Germinasi C; Frattini T; Meola G; Turconi AC; Bresolin N; Bassi MT
J Neurol Sci; 2006 Feb; 241(1-2):13-7. PubMed ID: 16325861
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias.
Hess E
Neurology; 2011 Nov; 77(22):1996-7; author reply 1997. PubMed ID: 22123782
[No Abstract] [Full Text] [Related]
20. Update on the pharmacotherapy of cerebellar and central vestibular disorders.
Kalla R; Teufel J; Feil K; Muth C; Strupp M
J Neurol; 2016 Apr; 263 Suppl 1():S24-9. PubMed ID: 27083881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
